Suppr超能文献

大剂量维库溴铵的神经肌肉阻滞:舒芬太尼麻醉期间心律失常与阻滞起效的比较

High-dose vecuronium neuromuscular block: a comparison of arrhythmias and onset of block during sufentanil anaesthesia.

作者信息

Sharpe M D, Murkin J M, Vannelli T

机构信息

Department of Anaesthesia, University Hospital, University of Western Ontario, London, Canada.

出版信息

Can J Anaesth. 1995 Aug;42(8):716-23. doi: 10.1007/BF03012671.

Abstract

This study compared the heamodynamic effects of sufentanil with those observed following concomitant sufentanil and high-dose vecuronium administration to determine whether vecuronium induces bradyarrhythmias. Sixty coronary artery bypass patients were stratified into beta blocker (n = 30) or non-beta blocker (n = 30) groups and following induction with sufentanil (9 +/- 3 micrograms.kg-1) and midazolam (0.07 +/- 0.04 mg.kg-1), received either succinylcholine 1 mg.kg-1 (SxCh), vecuronium 0.3 mg.kg-1 (Vec 0.3), or vecuronium 0.5 mg.kg-1 (Vec 0.5). Using a Holter ECG monitor, bradyarrhythmias were classified as mild (HR 46-50), moderate (HR 40-45) or severe (HR < 40). In the pre-induction period, there were no differences in the incidence of mild, moderate or severe bradyarrhythmias among the SxCh, Vec 0.3 or Vec 0.5 groups, in either the beta blocker or non-beta blocker groups. Following induction, there were similar reductions in mean heart rate and mean arterial pressure in all three muscle relaxant groups in both the beta and the non-beta blocker groups; however, there was no difference in the incidence of mild, moderate or severe bradyarrhythmias among the SxCh, Vec 0.3 or Vec 0.5 groups. The Vec 0.5 beta blocker group had a higher incidence of mild bradyarrhythmias (32 +/- 36%) than the Vec 0.5 non-beta blocker group (2 +/- 3%, P = 0.017). Using EMG recording, the onset time of maximal neuromuscular block for the Vec 0.3 group (108 +/- 17 sec) was longer (P < 0.05) than the SxCh (76 +/- 21 sec) and Vec 0.5 (82 +/- 13 sec) groups, which were similar.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

本研究比较了舒芬太尼的血流动力学效应与舒芬太尼和大剂量维库溴铵联合给药后的效应,以确定维库溴铵是否会诱发缓慢性心律失常。60例冠状动脉搭桥手术患者被分为β受体阻滞剂组(n = 30)或非β受体阻滞剂组(n = 30),在给予舒芬太尼(9±3微克·千克⁻¹)和咪达唑仑(0.07±0.04毫克·千克⁻¹)诱导后,分别接受琥珀胆碱1毫克·千克⁻¹(SxCh)、维库溴铵0.3毫克·千克⁻¹(Vec 0.3)或维库溴铵0.5毫克·千克⁻¹(Vec 0.5)。使用动态心电图监测仪,缓慢性心律失常被分为轻度(心率46 - 50次/分钟)、中度(心率40 - 45次/分钟)或重度(心率<40次/分钟)。在诱导前,SxCh组、Vec 0.3组或Vec 0.5组中,轻度、中度或重度缓慢性心律失常的发生率在β受体阻滞剂组和非β受体阻滞剂组中均无差异。诱导后,β受体阻滞剂组和非β受体阻滞剂组的所有三个肌肉松弛剂组的平均心率和平均动脉压均有相似程度的降低;然而,SxCh组、Vec 0.3组或Vec 0.5组中轻度、中度或重度缓慢性心律失常的发生率并无差异。Vec 0.5β受体阻滞剂组轻度缓慢性心律失常的发生率(32±36%)高于Vec 0.5非β受体阻滞剂组(2±3%,P = 0.017)。通过肌电图记录,Vec 0.3组达到最大神经肌肉阻滞的起效时间(108±17秒)比SxCh组(76±21秒)和Vec 0.5组(82±13秒)更长(P<0.05),而后两组相似。(摘要截断于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验